Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
 | UCB | 3 | - | +0,05 % | |
| ARGENX | 1 | 10 | +0,83 % | ||
| UMICORE | 1 | 2 | -0,19 % | |
| MONTEA | 1 | 1 | +2,33 % | |
| AB INBEV | - | 30 | +0,11 % | |
| MELEXIS | - | 4 | 0,00 % | |
| ELIA GROUP | - | 4 | -0,28 % | |
| AGEAS | - | 1 | +0,26 % | |
| KBC GROEP NV | - | 1 | +0,05 % | |
| GBL | - | 1 | -0,52 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:06 | Melexis N.V.: Melexis hosts its Capital Markets Day today | 2 | GlobeNewswire (USA) | ||
| Di | Montea Comm. VA Bottom Line Declines In Nine Months | 2 | RTTNews | ||
| Di | Umicore - Transparency notification by Silchester International Investors LLP | 4 | GlobeNewswire (USA) | ||
| Di | On a roll, UCB picks up another rare disease FDA approval | 3 | FiercePharma | ||
| Di | Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales | 7 | Investing.com | ||
| Di | UCB bags FDA okay for first drug to treat rare disease TK2d | 3 | pharmaphorum | ||
| Di | FDA approves UCB's Kygevvi for genetic mitochondrial disease | 3 | Pharmaceutical Technology | ||
| Mo | UCB: U.S. FDA approves KYGEVVI (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) | 77 | PR Newswire | Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d)... ► Artikel lesen | |
| Mo | GBL: GBL - Voting rights and denominator - Situation as at October 31, 2025 | 3 | Euronext | ||
| Mo | GBL: GBL - Transactions on GBL shares 03-11-2025 | 3 | Euronext | ||
| Mo | Syensqo SA: Acquisition of own shares | 152 | GlobeNewswire (Europe) | Press release (https://www.syensqo.com/en/newsroom/news-and-press-releases)
Communiqué de presse (https://www.syensqo.com/en/newsroom/news-and-press-releases)
Persbericht... ► Artikel lesen | |
| Mo | Melexis N.V.: Melexis: update on the share buy-back program | 9 | GlobeNewswire (USA) | ||
| Mo | Nextensa NV: PUBLICATION OF ATRANSPARENCY NOTIFICATION - ACKERMANS & VAN HAAREN | 3 | GlobeNewswire (USA) | ||
| Mo | Aedifica NV/SA: Publication relating to transparency notifications from the Goldman Sachs Group, Inc. & BlackRock, Inc. | 6 | GlobeNewswire (USA) | ||
| Mo | HS Hyosung to Acquire Umicore's Next-Generation Battery Core Business | 20 | BusinessKorea | ||
| Mo | UBS stuft AB Inbev auf 'Buy' | 604 | dpa-AFX-Analyser | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für AB Inbev mit einem Kursziel von 68 Euro auf "Buy" belassen. Das Aktienrückkaufvolumen von 6 Milliarden Dollar in den kommenden... ► Artikel lesen | |
| Mo | GBL: GBL - Portfolio simplification with significant monetization of GBL Capital | 7 | Euronext | ||
| Mo | HS Hyosung enters battery material sector with Umicore deal | 18 | Korea Times | ||
| Mo | Ageas expands partnership with RAC | 2 | Insurance Business America | ||
| Mo | HS Hyosung Acquires Belgian Umicore's Silicon Anode Material Subsidiary | 14 | BusinessKorea |
1 2 3 4 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .